Sanofi says U.S. FDA to fast track Fabry therapy review

[April 28, 2015]  PARIS (Reuters) - French drugmaker Sanofi said on Tuesday that the U.S. Food and Drug Administration has agreed to speed up the review of its drug application for a new Fabry disease treatment.

Sanofi said its Genzyme unit was enrolling patients in a mid-stage Phase IIa trial of the "GZ/SAR402671" therapy.

Fabry disease is an inherited, potentially fatal disorder characterized by the buildup of a particular type of fat that results in cell damage, leading to pain, hearing loss, kidney failure, heart attacks and strokes.

(Reporting by James Regan; Editing by Emelia Sithole-Matarise)

[© 2015 Thomson Reuters. All rights reserved.]

Copyright 2015 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.